Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X E-ISSN: 1527-7755
United States
English
Health Sciences

Journal Metrics

Articles 18,540
Authors 89,673
Citations 0
H-Index 0

About this Journal

A leading journal in Health Sciences published by Lippincott Williams & Wilkins. Imported from OpenAlex (ID: https://openalex.org/S15137598).

18,540
Articles
89,673
Authors
3
Volumes
70
Issues
2025–2026
Year Range

Journal Analytics

Publication Trend

Articles per Volume

Author Growth

Monthly Publications (Last 12 Months)

Top Contributing Authors

1 Neeraj Agarwal
127 articles
2 Rana R. McKay
126 articles
3 Toni K. Choueiri
103 articles
4 Neal D. Shore
94 articles
5 Takayuki Yoshino
93 articles
6 Lin Shen
84 articles
7 Kyaw Zin Thein
82 articles
8 Daniel Thomas Jones
81 articles
9 Sumanta Kumar Pal
74 articles
10 Alexander I. Spira
68 articles

Latest Articles

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica, Giandomenico Roviello et al. Aug 20, 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud, Alexandra Drakaki et al. Aug 20, 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando, Akihiko Shimomura et al. Aug 20, 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan, Georgina El Hajjar et al. Aug 20, 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble, Thomas A. Hope et al. Aug 20, 2026 10.1200/jco-26-01001

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

Curtis A. Lachowiez, Joshua F. Zeidner, Jad Othman et al. Aug 20, 2026 10.1200/jco-26-01801

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)

Rana R. McKay, Karla V. Ballman, Pamela J. Atherton et al. Aug 20, 2026 10.1200/jco-26-01135

End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma

Jonathan W. Friedberg Aug 20, 2026 10.1200/jco-26-01188

Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective

Elysia Donovan, Timothy J. Whelan Aug 20, 2026 10.1200/jco-26-00997

Taking Responsibility

Katherine Hicks-Courant Aug 20, 2026 10.1200/jco-25-02100

Volumes & Issues